alexsl
- Jones Trading has downgraded Theravance Biopharma (TBPH) to hold from buy following the announcement earlier Monday that Zymeworks (ZYME) is acquiring the company in a $929M deal.
- Analyst Debanjana Chatterjee wrote that the transaction does not pose antitrust risk or
